Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS.

ABSTRACT:

Introduction

MRTX1133 is a selective and reversible small molecule inhibitor of KRAS (G12D), which significantly delays the progression of solid tumors. However, no study on the absorption, distribution, and excretion of MRTX1133.

Methods

A fast ultra-high performance liquid chromatography-tandem quadrupole mass spectrometry method was developed for the determination of MRTX1133 in rat plasma, tissue homogenate, and urine. The method applied to the pharmacokinetics, bioavailability, tissue distribution, and excretion of MRTX1133 after oral administration (25 mg/kg) and intravenous administration (5 mg/kg).

Results

The calibration curve for MRTX1133 in plasma and other homogenates was linear, with r ² > 0.99. The intra- and inter-day accuracies were r

SUBMITTER: Lu W 

PROVIDER: S-EPMC11693508 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature